Products

Dinitolmide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

    • Product Name: Dinitolmide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: admin@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    Specifications
    HS Code 482857
    Chemical Name 2-Methyl-3,5-dinitrobenzamide
    Cas Number 148-01-6
    Molecular Formula C8H7N3O5
    Molecular Weight 225.16 g/mol
    Appearance Yellow to brownish-yellow crystalline powder
    Solubility Practically insoluble in water; soluble in dimethylformamide, acetone, and hot ethanol
    Melting Point 180°C to 182°C
    Storage Conditions Store in a well-closed container, protected from light, at controlled room temperature

    As an accredited Dinitolmide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Dinitolmide Pharma Grade API packed in 25 kg HDPE drums with double polythene liner bags, ensuring stability and safety.
    Container Loading (20′ FCL) One 20′ FCL loaded with sealed drums of Dinitolmide Pharma Grade API, safely secured for oral, injectable, and granule pharmaceutical use.
    Shipping Shipments of Dinitolmide Pharma Grade API are handled in sealed, moisture-protected drums with tamper-evident seals. Cold-chain is not required; store in a cool, dry area. Documentation includes MSDS, COA, and transport declaration. Strict compliance with pharmaceutical shipping regulations ensures safe, traceable delivery worldwide.
    Storage Store in a tightly sealed original container in a cool, dry, well-ventilated area. Protect from moisture, direct sunlight, and excessive heat. Maintain room temperature, ideally between 15–30°C. Keep away from incompatible substances and food handling areas. Ensure container remains closed when not in use to preserve the API’s potency, purity, and stability throughout its shelf life.
    Shelf Life Shelf Life: 24 months from manufacture when stored in original, tightly closed container, protected from light and moisture.
    Application of Dinitolmide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

    In broiler feed mills operating under integrated poultry production contracts, dinitolmide is introduced as a low-inclusion coccidiostat blended into complete feed for control of Eimeria tenella, Eimeria acervulina, and Eimeria maxima. The registered in-feed concentration for broiler chickens is 125 mg/kg finished feed, equivalent to 125 g/t; a 5% w/w dinitolmide premix is therefore metered at 2.5 kg/t when the carrier has been standardized for bulk density and particle size. Dry blending is performed in a twin-ribbon mixer or twin-shaft paddle mixer with a working volume not exceeding 80% of geometric capacity; the API premix is first geometrically diluted with a dust-controlled carrier such as calcium carbonate or ground rice hulls at a 1:10 ratio before addition to the main mixer. Potency distribution is evaluated by taking not fewer than 10 sampling points through the discharge stream under ISO 6497:2002; acceptance is set at a relative standard deviation below 10% for active ingredient assay across all points. Regulatory obligations for medicated feed manufacturing in the United States fall under 21 CFR Part 225 current good manufacturing practice for medicated feeds and 21 CFR 558.128 for dinitolmide in medicated feed; residue tolerances appear in 21 CFR Part 556. European Union feed additive registration is absent for dinitolmide under Regulation (EC) No 1831/2003, so this production route is not intended for EU-origin poultry feed unless national derogations apply. The terminal products from this production route are Type C medicated broiler starter, grower, and finisher crumbles or mash; these products are typically pelleted at conditioner temperatures below 85°C unless a dedicated stability study has been executed. A batch-to-batch variance source observed on production lines is segregation of the dinitolmide premix in hopper screw feeders when the carrier particle size distribution shifts above 200 µm; this is mitigated by specifying a carrier with a bulk density within ±10% of the main feed matrix.

    Pharmaceutical-grade dinitolmide API intended for this route must be distinguished from technical-grade feed additive by residual solvent profile and particle-size distribution. The API specification should include not less than 98.5% assay on dried basis and a particle size with 90% passing 150 µm mesh, because low-dose blending performance is more sensitive to particle-size bias than to chemical purity once the active content exceeds the feed-grade threshold. When the feed mill uses a horizontal ribbon mixer, geometric dilution ratios of 1:10 repeated for two cycles are used before the active premix is added to the 1000 kg main batch; when a vertical-shaft paddle mixer is used, the pre-blend is introduced at the midpoint of the vessel during filling to avoid dead zones near the side wall. The blend uniformity test is not a single-point assay; it is a destructive composite of 10 individual samples taken at discharge intervals and the coefficient of variation must remain below 10% relative to the mean assay. In exporting regions that do not recognize 21 CFR 558.128, the registrant is often required to hold a separate national feed additive authorization and to submit a residue depletion file showing that dinitolmide residues fall below the national tolerance; the Codex Alimentarius maximum residue limit for dinitolmide has not been established, so the exact residue limit must be confirmed with the local competent authority before batch release.

    What Process Windows Govern Steam-Pelleted Turkey Poult Feeds Containing Dinitolmide?

    Steam-pelleted turkey poult rations introduce a second thermodynamic environment that is not present in simple mash blending. The turkey final feed concentration is 250 mg/kg complete feed; a 5% w/w dinitolmide premix is metered at 5.0 kg/t to achieve that target. Mash is conditioned with live steam at 75–80°C for 30–45 s; pellet die length-to-diameter ratio is typically maintained between 8:1 and 10:1, and cooled pellet temperature is returned to within 3°C of ambient before loadout. Published kinetic data for dinitolmide degradation under steam conditioning is limited; therefore each change in conditioner temperature above 80°C requires a formal stability batch with assay retention measured by extraction from cooled pellets rather than from the mash. Fines recycling from pellet cooler screens can shift the particle size distribution and cause uneven distribution of active premix in the finished bulk; the recycle stream is either diverted or reintroduced after grinding through a 2.0 mm screen. Compliance is governed by 21 CFR 558.128, 21 CFR Part 225, and ISO 22000:2018 in integrated feed safety management; export turkey meat programs may additionally require bilateral national residue limits because Codex Alimentarius maximum residue limits for dinitolmide have not been established. Terminal products are pelleted turkey starter, turkey grower crumbles, and post-pellet liquid-fat coated rations where the fat coating is applied after active assay confirmation to avoid solvent or temperature interactions.

    Thermal degradation and assay retention are measured by sampling pellets at the cooler discharge and not by relying on mash assay values, because steam conditioning redistributes moisture and can alter extractability of dinitolmide from the feed matrix. Recovery from pellets with a moisture content above 12% at sampling may be underestimated if the extraction method does not include a water-miscible solvent equilibration step. The die retention time and compression ratio affect pellet hardness and the subsequent release of active in the bird gut; a pellet hardness above 10 kg crushing strength may reduce the rate of disintegration in gizzard contents, although published data for dinitolmide release from hard pellets is limited. The feed mill should therefore maintain pellet hardness between 4 kg and 8 kg for turkey starter crumbles, and should verify that the fine fraction smaller than 0.5 mm does not exceed 10% of the bagged product. Terminal fat coating is applied only after the cooled pellet assay confirms retention of not less than 95% of theoretical dinitolmide; if retention falls below 95%, the batch is segregated for rework, and the conditioner temperature is reduced by 5°C increments in the next batch until assay retention returns to specification.

    Because dinitolmide is not commercially available as an aqueous injectable and its pharmacological action is primarily lumenal, injectable product development is not supported by published data; the practical non-pelleted oral route for smaller flock use is a dry granule top dress. No commercial tablet or capsule product is documented for dinitolmide in major poultry markets; individual oral tablet administration is incompatible with mass medication of floor-reared flocks. For floor-reared pullets, a 1% w/w dinitolmide granule premix is added to complete grower mash at 12.5 kg/t to deliver 125 mg/kg final feed. Mixing at the farm is conducted with a portable paddle mixer for not less than 5 minutes, and the batch size is limited to the mixer’s recommended capacity, often 500–1000 kg. The finished top-dress mash is consumed immediately to reduce settling and moisture uptake; storage beyond 48 hours requires re-mixing before feeding. This route is not permitted in all jurisdictions; the user must verify 21 CFR 558.128 registration status for specific geographical use and confirm that on-farm mixing is allowed under local good manufacturing practice for medicated feeds. Terminal products are medicated grower mash for pullet rearing and short-cycle non-commercial broiler feeds; pelleted versions of these top-dressed feeds are not recommended without re-validation because the carrier dilution differs from commercial Type C feed. Pharmacopoeial monographs for dinitolmide are limited; the API buyer should request the manufacturer’s certificate of analysis against the seller’s internal specification and, if available, a VICH GL18 residue marker conformity statement. The absence of a Codex residue limit means export-oriented farms should conduct residue depletion studies with the specific premix rather than relying solely on published withdrawal periods.

    When a Multi-Species Feed Mill Uses Displacement Flushing for Dinitolmide Carryover Control

    Carryover control is a separate downstream unit operation when the same mixer and elevator legs process medicated turkey feed at 250 mg/kg and subsequent non-medicated withdrawal feed. The residual dinitolmide concentration after non-medicated flush is measured at the mixer discharge and at the finished-feed bin; the analytical method should reach a limit of quantification of 0.1 mg/kg in dry feed. A displacement flush of ground corn or non-medicated broiler feed at 1000 kg through the entire conveying path is a starting point, but the acceptance criterion is not flush weight alone; it is the measured carryover concentration falling below 0.5% of the next target inclusion, which for a subsequent non-medicated cleanup batch is effectively below the LOQ of 0.1 mg/kg. Sampling points follow ISO 6497:2002; production validation should include the top and bottom of bucket elevator legs, mixer discharge, pellet cooler, and finished-loadout bin. Regulatory oversight under 21 CFR Part 225 requires written cleanout procedures for medicated feed equipment; the sequence and flush volume are retained as batch records. Terminal products from this operation are non-medicated withdrawal feed, unmedicated breeder or layer rations, and the next medicated feed batch after carryover is cleared. The dinitolmide withdrawal period for broiler chickens has historically been listed as 5 days in the United States approval; this is a product-level regulatory parameter and should not be substituted for national residue surveillance data.

    Loading and flushing sequences are validated by measuring the concentration gradient at the elevator boot and at the top discharge; the highest residual usually occurs at the pellet die and cooler screens where fines adhere. The flush material should have a similar particle size to the medicated feed; using whole grain as flush can leave drug-bearing fines in dead zones. After a medicated run at 250 mg/kg, a flush of 1000 kg ground corn through the mixer and elevator legs may reduce carryover to below 1 mg/kg, but the operator must collect at least 10 sampling points and the mean residual must be below the validated limit. Written cleanout procedures under 21 CFR Part 225 include equipment disassembly frequency and the use of a dedicated medicated feed mixer where feasible. In facilities that export to multiple jurisdictions, carryover limits must be aligned with the strictest destination market, not the country of production.

    Analytical Reference Standard Handling and Method Transfer for Finished Feed Assay

    When dinitolmide API is used outside direct formulation, it functions as a working reference standard for residue surveillance and medicated feed assay transfer. The standard material is assigned a purity of >99.0% by HPLC-UV against a secondary reference, and the stock solution is prepared in acetonitrile at 100 µg/mL; matrix-matched spikes for broiler feed are set at 125 mg/kg and for turkey feed at 250 mg/kg to bracket the registered use levels. Validation follows ICH Q2(R1) for specificity, linearity, accuracy, and precision; laboratory competence is accredited under ISO/IEC 17025:2017. The extraction procedure uses acetonitrile-water (70:30 v/v) with a dispersive solid-phase cleanup for feed lipids; detection is by reversed-phase HPLC with UV absorbance or LC-MS/MS when residue-level sensitivity below 0.1 mg/kg is required. Terminal products from this application are analytical reference standards, matrix-matched calibrators, quality control feed samples, and proficiency testing materials for export poultry residue monitoring. Published data for this specific configuration is limited for some matrix effects; linearity and recovery should be re-established per feed matrix because the fat content of broiler finisher feed above 8% can suppress UV detection sensitivity if cleanup is insufficient.

    The reference material production process itself uses a separate small-scale batch after lot release; the API is precisely weighed and dissolved in acetonitrile in amber volumetric glassware to prevent photodegradation. Linearity is assessed over the range 10%–150% of the target feed concentration, which corresponds to 12.5–187.5 mg/kg for broiler feed and 25–375 mg/kg for turkey feed. Recovery at three levels should fall within 85%–110%; matrix effects in finisher feed containing high fat require azeotropic solvent evaporation or a C18 solid-phase extraction cleanup before injection. The terminal products are not medicated feeds but certified reference material, method validation kits, and proficiency panels distributed to export slaughterhouse laboratories. Published pharmacopoeial reference standards for dinitolmide are not available in all regions; therefore the API supplier’s working standard should be cross-validated against a national veterinary drug residue standard if one exists.

    Free Quote

    Competitive Dinitolmide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615365186327

    Email: admin@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Dinitolmide API, CAS 148-01-6, is the nitrotoluamide derivative 3,5-dinitro-2-methylbenzamide, molecular formula C8H7N3O5 and molecular mass 225.16 g/mol. The product model designation includes the dosage-form compatibility statement “Tablet / Capsule / Granule / Injection, Oral & Injectable” and is further differentiated by particle size grade: standard crystalline material for feed premixes and oral granules, and micronized material for low-dose tablets, capsule blends, oral suspensions, and injectable development. The term practically insoluble corresponds to the USP General Notices definition requiring more than 10,000 parts of solvent for one part of solute. Published aqueous solubility data for dinitolmide in the pH range 3–9 are limited, but the absence of a basic centre indicates that simple pH adjustment does not produce a dissolved ionized form. Pharmaceutical grade release testing should include identity, assay, related substances, residual solvents, loss on drying, sulphated ash, and particle size before the API is used in any of the listed dosage forms.

    Current compendial monographs for dinitolmide are primarily veterinary; no harmonized human-use monograph is available. Batch release should therefore follow the applicable marketing authorization and manufacturing site specification, in addition to current good manufacturing practice for active substances under VICH and national requirements. Because the molecule contains a nitroaromatic chromophore, closed containers and opaque liner systems are used during handling and distribution. Residual solvent control should conform to VICH GL18, and elemental impurities should be evaluated against ICH Q3D where adopted for veterinary products. The designation “pharma grade” does not establish sterility or endotoxin compliance; those attributes are controlled on the finished sterile product.

    Which Physicochemical Specifications Control Dinitolmide API Release?

    Release specifications for dinitolmide API are established from the official veterinary monograph and the registered manufacturer’s data. Identification is performed by infrared absorption spectrophotometry against a qualified reference standard. Assay is typically performed by reversed-phase high-performance liquid chromatography with ultraviolet detection in the range 220–260 nm. Related substances are determined by the same chromatographic method with a total impurity limit that reflects the intended route of administration; for raw API, a representative acceptance criterion is ≤ 1.0% total related substances, with any individual unspecified impurity controlled at ≤ 0.10%. Loss on drying after drying at 105 °C is typically not more than 0.5%, and sulphated ash is not more than 0.1%. Particle size is specified as a separate grade attribute: standard crystalline material may show a D90 in the range 100–200 µm, while a micronized grade intended for injectable or low-dose solid dosage forms should demonstrate a D90 of ≤ 10 µm by laser diffraction. The exact acceptance limits vary among pharmacopoeial monographs and regulatory files; the values above are representative industrial release targets, not a substitute for the current legal specification.

    Representative release specification matrix for dinitolmide API
    AttributeTypical criterionReference method
    AppearanceYellow crystalline powderVisual examination
    Identification by IRConcordant with reference standardPh. Eur. 2.2.24; USP <197>
    Assay on dried basis98.0%–102.0%Ph. Eur. 2.2.29; USP <621>
    Loss on drying≤ 0.5%Ph. Eur. 2.2.32; USP <731>
    Sulphated ash≤ 0.1%Ph. Eur. 2.4.16; USP <281>
    Total related substances≤ 1.0%Ph. Eur. 2.2.29
    Residual solventsConforms to VICH GL18Headspace GC
    Particle size, micronized gradeD90 ≤ 10 µmUSP <429>

    Because the API is used in multiple dosage forms, additional in-process controls are required at the finished product stage. For injectable use, the starting material is not automatically sterile or pyrogen-free; the finished product must establish sterility per USP <71>, bacterial endotoxin limits per USP <85>, and particulate matter per USP <788>. For oral solid dosage forms, blend uniformity per USP <905> and disintegration or dissolution per USP <701> or <711> apply to the finished product, not to the raw API. The nitrotoluamide structure is light-sensitive; storage in tight, dark containers at controlled room temperature below 25 °C is typical, with excursions controlled by registered stability data.

    For tablet and capsule production, the principal process risk is low-dose blend uniformity when dinitolmide is present as a minor component. A blend uniformity of 90%–110% of label claim with relative standard deviation not more than 5.0% is a common acceptance range before compression or encapsulation. Micronized dinitolmide increases the number of particles per unit dose but also increases particle-particle adhesion and electrostatics; blends often require colloidal silicon dioxide at 0.5%–1.0% by weight and intimate pre-blending with a portion of lactose monohydrate or microcrystalline cellulose. If direct compression is used, the API D90 should be ≤ 150 µm for acceptable content uniformity; if dry granulation is used, roller compaction ribbon density is typically maintained within 0.9–1.2 g/cm3, but published data for dinitolmide ribbon densification are limited. Wet granulation may be preferred when the dose is low and the API is micronized because a binder solution of povidone K30 at 2%–5% solids can reduce segregation. Granulation endpoint is better controlled by impeller torque or power consumption than by fixed time; final granule moisture before lubrication should not exceed 2.0% if the API is sensitive to hydrolysis under damp conditions. Drying should use a fluid-bed dryer with inlet air temperature not exceeding 60 °C to avoid unnecessary thermal stress on the nitroaromatic chromophore. Published data for dinitolmide-specific thermal degradation kinetics are limited, so forced degradation studies are required before selecting a drying method.

    Granule products containing dinitolmide are usually prepared by high-shear wet granulation followed by extrusion or by fluid-bed top-spray granulation. In a high-shear granulator, an impeller speed of 200–300 rpm and a chopper speed of 1500–2500 rpm are used as starting parameters, with addition of purified water or binder solution at a controlled rate of 10–20 mL/min/kg. These ranges are general process benchmarks for low-soluble crystalline APIs; they should be refined using torque response and granule size distribution. The target granule size for tablet compression is often between 125 µm and 850 µm, with less than 10% fines below 75 µm. Drying in a fluid-bed dryer at an inlet air temperature of 40–60 °C should continue until loss on drying is below 2.0%. Overdrying can increase granule friability, while residual moisture above 2.5% can cause picking and sticking during tablet compression. Capsule filling with granules or milled blends requires moisture control to prevent softening of gelatin capsules; if hypromellose capsules are used, the shell moisture specification should be checked against the fill formulation.

    When Injectable Formulation Is Considered for a Poorly Water-Soluble Veterinary API

    Injectable use of dinitolmide presents a formulation conflict between the required particle size and the low aqueous solubility of the nitrotoluamide crystal. A true solution cannot be achieved by simple pH adjustment because the molecule does not contain an ionizable centre in the pH range 3–9; solubilization requires a co-solvent system, inclusion complex, surfactant micellization, or a suspended solid. If a co-solvent approach is selected, propylene glycol and macrogol 400 are typical non-aqueous solvents, but precipitation upon dilution with physiological media must be tested using a dynamic dilution method. A large co-solvent content may exceed the tolerance in the target species and may alter the tonicity of the injection; the final solution should meet USP <785> for osmolality or a suitable animal health equivalent. Published data for dinitolmide solubility in co-solvent systems are limited. For a sterile suspension, particle size reduction must be carried out before aseptic compounding. Terminal sterile filtration is not applicable because the suspended crystals exceed the 0.22 µm membrane pore size. Terminal moist-heat sterilisation at 121 °C for 15 min may be evaluated only if forced degradation demonstrates no adverse change in related substances; nitrated aromatic compounds are susceptible to decomposition under extreme conditions, and a lower-temperature aseptic process may be required. The suspended particles should show a D90 of ≤ 5 µm and a D50 of ≤ 1.5 µm for a typical parenteral suspension, but this target may be relaxed for intramuscular depot products where a larger particle size is intentionally used. Aseptic filling of an injectable suspension should take place in an ISO 14644-1 Class 5 environment with a restricted access barrier system or isolator. The finished injectable must be tested for sterility per USP <71>, bacterial endotoxins per USP <85>, and subvisible particulate matter per USP <788>. No harmonized dinitolmide injection monograph is available; therefore, the formulation must be justified through pharmaceutical development and validated by the manufacturing site.

    An alternative sterile injectable presentation is a lyophilized product, but this is only suitable if the API can be dissolved in a co-solvent and then freeze-dried. Because dinitolmide is poorly water-soluble, the lyophilization cake would require careful characterization of residual solvent and polymorphic form. The nitrobenzamide crystal may undergo polymorphic or habit changes during lyophilization; the resulting solid state must be confirmed by X-ray powder diffraction per USP <941> and differential scanning calorimetry. Published data for dinitolmide injectable formulations are limited, so this specific configuration should not be assumed to be commercially established.

    Dinitolmide Versus Triazine and Ionophore Coccidiostats in Dosage-Form Design

    Compared with the triazine coccidiostats diclazuril and toltrazuril, dinitolmide has a smaller nitrotoluamide structure, molecular mass 225.16 g/mol, and a different chromophore. The molecular mass of diclazuril is 407.63 g/mol and that of toltrazuril is 425.37 g/mol. This mass difference means that a fixed weight of dinitolmide contains more molecules per gram than the same weight of the triazine compounds, but dose equivalence is not directly proportional because potency and pharmacokinetics differ. In formulation, all three compounds show practically insoluble aqueous solubility; therefore, particle size, wetting, and suspension rheology dominate the design rather than salt selection. Unlike monensin sodium, an ionophore with molecular mass 692.85 g/mol, dinitolmide does not function primarily through alkali metal cation complexation and does not require the same ion-balance controls in the finished product. Dinitolmide is a nitroaromatic compound; this structural feature requires light protection and oxidative-stability assessment, whereas non-nitrated triazine compounds may have different photostability profiles.

    Dosage-form-relevant physicochemical differences among coccidiostats
    ParameterDinitolmideDiclazurilToltrazurilMonensin sodium
    Chemical classNitrotoluamideTriazine derivativeTriazine derivativePolyether ionophore
    Molecular mass225.16 g/mol407.63 g/mol425.37 g/mol692.85 g/mol
    Aqueous solubilityPractically insolublePractically insolublePractically insolubleLow aqueous solubility; ionophore complexation behaviour
    Primary commercial presentationsFeed premix, oral solids, suspensionsOral suspension, feed additiveOral suspension, drinking waterFeed additive, oral solution
    Key formulation constraintLow solubility, particle size control for dose uniformityLow solubility, wet-milling requiredLow solubility, suspension stabilizationIon complexation and pH-dependent stability

    Because the products belong to different chemical classes, cross-substitution in a formulation should not be performed without revalidation of drug substance particle size, excipient compatibility, and stability. The selection of dinitolmide instead of a triazine or ionophore should be based on the registered indication, target species, regional approval, and applicable resistance-monitoring program, not solely on physicochemical convenience. In manufacturing, dinitolmide can be integrated into a common low-dose animal health granulation line, but line segregation and cleaning validation must account for its nitroaromatic residual detection and low aqueous solubility; rinsing with purified water alone is generally insufficient, and a solvent-based cleaning step may be required in dedicated or multi-product facilities.

    Top